Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Efficacy and safety of insulin detemir compared with NPH insulin for women with type-1 diabetes mellitus (CROSBI ID 578646)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa

Ivanišević, Marina ; Đelmiš, Josip Efficacy and safety of insulin detemir compared with NPH insulin for women with type-1 diabetes mellitus // 41st Annual meeting of DPSG / DPSG (ur.). Frascati: DPSG, 2009. str. 35-35

Podaci o odgovornosti

Ivanišević, Marina ; Đelmiš, Josip

engleski

Efficacy and safety of insulin detemir compared with NPH insulin for women with type-1 diabetes mellitus

Background. In recent years, the basal insulin analogue Detemir has been introduced. It is developed to improve upon the limitations of Neutral Protamine Hagedorn insulin (NPH) and other conventional basal insulins, which have an inadequate duration of action, a marked peak glucose-lowering effect and variability in response from one injection to another. Detemir might help to overcome some of the barriers to insulin initiation and optimization, including concerns over hypoglycemia and weight gain. The efficacy and safety of insulin Detemir (Levemir®), a long-acting human insulin analogue plus insulin aspartat, were compared with NPH plus insulin aspartat for pregnant women with type-i diabetes mellitus (DM-i). Methods. In a randomized, parallel-group, open-labeled trial, 28 women with uncomplicated DM-1 (age 30.3 ± 4.6 years, HbA1c < 7%) were randomized to receive Detemir (2X daily) plus insulin aspartat (I. group ; n=14) and NPH (2X daily) plus insulin aspartat (II. group ; n=14). The trial period extended from first trimester (from 6-10 weeks) to 6 weeks postpartum. Results. Both treatment groups maintained good overall glycemic control during the study. At beginning of the study HbA1c did not differ between two groups: 6.56 ± 0.83:6.82 ± 0.58 ; n.s.). At the end of the study we found statistically significant decrease in HbA1c in I. group of patients (5.8 ± 0.74 : 6.4 ± 0.96 ; p<0.05). No major hypoglycemic events were reported during the study in both groups. The mean postprandial glucose concentrations in the I. group were lower than in the II. group (5.66 ± 1.o3 mmol/: 6.24 ± 1.31 mmol/L). Newborns weight did not differ between two groups (3286.25 ± 443g : 3114 ± 626.o8g). Two deliveries were preterm in both groups (at 35th and 36th weeks of pregnancy) and 26 deliveries were at term (> 38th weeks of pregnancy), and newborns were healthy. Conclusion. Detemir was more effective than NPH in decreasing postprandial glucose concentrations. Overall safety and effectiveness of Detemir were comparable to NPH in pregnant women with DM-1.

efficacy; safety; insulin; detemir; NPH; type 1 diabetes mellitus

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

35-35.

2009.

objavljeno

Podaci o matičnoj publikaciji

41st Annual meeting of DPSG

DPSG

Frascati: DPSG

Podaci o skupu

41st Annual meeting of DPSG

poster

25.09.2009-28.09.2009

Rim, Italija

Povezanost rada

Kliničke medicinske znanosti